Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price ManipulationAccesswire • 11/25/24
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development TeamAccesswire • 08/09/24
24/7 Market News Publishes Report Covering Functional Beverage Market, Featuring FSD PharmaNewsfile Corp • 07/25/24
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of ShareholdersNewsfile Corp • 07/23/24
24/7 Market News Publishes Report Covering Biotech Developments, Featuring FSD PharmaNewsfile Corp • 07/23/24
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.Accesswire • 06/28/24
FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in AustraliaAccesswire • 06/27/24
FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business ApplicationsAccesswire • 06/13/24
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol IntoxicationAccesswire • 06/04/24
FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus InterestAccesswire • 05/31/24
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in AustraliaAccesswire • 05/07/24
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol IntoxicationAccesswire • 04/30/24
FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd(TM)Accesswire • 04/25/24
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)Accesswire • 04/22/24
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and ProductsAccesswire • 04/17/24
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol ConsumptionAccesswire • 04/15/24
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNewsfile Corp • 04/08/24
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy AdultsAccesswire • 03/27/24
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 ForumAccesswire • 03/05/24